- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
REGENXBIO to Present at Muscular Dystrophy Association Conference
Biotech firm to share updates on gene therapy research at annual MDA event.
Published on Mar. 4, 2026
Got story updates? Submit your updates here. ›
REGENXBIO Inc., a biotechnology company focused on gene therapy treatments, has announced that it will be presenting at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. The presentations will provide updates on REGENXBIO's ongoing research and development efforts in the field of muscular dystrophy.
Why it matters
As a leading biotech company in the gene therapy space, REGENXBIO's participation in the MDA conference underscores its commitment to advancing treatments for devastating genetic disorders like muscular dystrophy. The presentations will give the research community and patient advocates an inside look at the company's pipeline and progress.
The details
REGENXBIO will be delivering multiple presentations at the 2026 MDA conference, covering topics such as the latest data from its clinical trials and preclinical studies of gene therapy candidates for various forms of muscular dystrophy. The company's researchers will share insights into the science behind their approaches and the potential impact these therapies could have for patients.
- The 2026 MDA Clinical & Scientific Conference will take place from March 3-6, 2026.
- REGENXBIO's presentations are scheduled for March 4, 2026.
The players
REGENXBIO Inc.
A clinical-stage biotechnology company focused on developing gene therapy treatments for genetic disorders, including various forms of muscular dystrophy.
The takeaway
REGENXBIO's participation in the MDA conference demonstrates the company's leadership in the gene therapy field and its commitment to advancing treatments for patients with debilitating genetic conditions like muscular dystrophy. The presentations will provide the research community with valuable insights into the company's pipeline and progress.
